147 related articles for article (PubMed ID: 38538256)
1. A Novel Cholesterol Metabolism-Related lncRNA Signature Predicts the Prognosis of Patients with Hepatocellular Carcinoma and Their Response to Immunotherapy.
Lei H; Xiang T; Zhu H; Hu X
Front Biosci (Landmark Ed); 2024 Mar; 29(3):129. PubMed ID: 38538256
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
3. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
4. Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.
Zhou P; Lu Y; Zhang Y; Wang L
Front Oncol; 2021; 11():661758. PubMed ID: 34277410
[TBL] [Abstract][Full Text] [Related]
5. Identification of a Novel N7-Methylguanosine-Related LncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma and Experiment Verification.
Yang C; Zhang L; Hao X; Tang M; Zhou B; Hou J
Curr Oncol; 2022 Dec; 30(1):430-448. PubMed ID: 36661684
[TBL] [Abstract][Full Text] [Related]
6. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
7. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
8. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer.
Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J
BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833
[TBL] [Abstract][Full Text] [Related]
10. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
11. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
Zhu J; Huang Q; Liu S; Peng X; Xue J; Feng T; Huang W; Chen Z; Lai K; Ji Y; Wang M; Yuan R
Front Immunol; 2022; 13():856186. PubMed ID: 35479067
[TBL] [Abstract][Full Text] [Related]
12. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
14. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
15. Identification of metabolism-related long non-coding RNA (lncRNA) signature predicts prognosis and immune infiltrates in hepatocellular carcinoma.
Wang X; Qian J; Yao N; Pocha C; Kang KJ; Angelico R; Zhu G
Ann Transl Med; 2022 May; 10(10):595. PubMed ID: 35722420
[TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a m7G-related lncRNA signature for predicting the prognosis and therapy response in hepatocellular carcinoma.
Peng YL; Dong YF; Guo LL; Li MY; Liao H; Li RS
PLoS One; 2023; 18(8):e0289552. PubMed ID: 37535570
[TBL] [Abstract][Full Text] [Related]
17. Identification of a DNA damage repair-related LncRNA signature for predicting the prognosis and immunotherapy response of hepatocellular carcinoma.
Huang F; Zhang C; Yang W; Zhou Y; Yang Y; Yang X; Guo W; Wang B
BMC Genomics; 2024 Feb; 25(1):155. PubMed ID: 38326754
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.
Li R; Jin C; Zhao W; Liang R; Xiong H
BMC Gastroenterol; 2022 Nov; 22(1):450. PubMed ID: 36344926
[TBL] [Abstract][Full Text] [Related]
19. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.
Huang S; Zhang J; Lai X; Zhuang L; Wu J
Front Mol Biosci; 2021; 8():781307. PubMed ID: 35004851
[No Abstract] [Full Text] [Related]
20. A New Ferroptosis-Related lncRNA Signature Predicts the Prognosis of Bladder Cancer Patients.
Chen M; Nie Z; Li Y; Gao Y; Wen X; Cao H; Zhang S
Front Cell Dev Biol; 2021; 9():699804. PubMed ID: 34869304
[No Abstract] [Full Text] [Related]
[Next] [New Search]